Correction to: Leukemia https://doi.org/10.1038/s41375-021-01125-4, published online 22 January 2021

In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azacitidine alone arm. Instead of n = 30 and n = 29 as originally published, these have now been corrected to n = 29 for pevonedistat + azacitidine and n = 30 for azacitidine. No changes were required to the response rate percentages as these were calculated using the correct denominators.

The updated files are attached to this correction.